NIH Media Bias for Past 90 Days

Average Social Media Shares: 425          Average Emotion: 0          Prescription Bias: 1

NIH Most Emotional Articles

Methamphetamine overdose deaths rise sharply nationwide

Researchers propose that humidity from masks may lessen severity of COVID-19

NIH Most Shared Articles

Researchers propose that humidity from masks may lessen severity of COVID-19

Blood test shows promise for early detection of acute heart transplant rejection

Combination treatment for methamphetamine use disorder shows promise in NIH study

NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms

NIH Most Prescriptive Articles

Timing is of the essence when treating brain swelling in mice

To end HIV epidemic, we must address health disparities

NIH Most Recent Articles

Drug testing approach uncovers effective combination for treating small cell lung cancer


var addthis_config ={ ui_508_compliant: true}Small cell lung carcinoma cellsParth Desai, M.D., National Cancer InstituteResearchers from the National Institutes of Health have identified and tested a drug combination that exploits a weakness in small cell lung cancer (SCLC), an aggressive, dangerous cancer. The scientists targeted a vulnerability in how the cancer cells reproduce, increasing already high levels of replication stress ­­-- a hallmark of out-of-control cell growth in many cancers that can damage DNA and force cancer cells to constantly work to repair themselves. In a small clinical trial, the drug duo shrank the tumors of SCLC patients. The team reported its findings April 12 in Cancer Cell.While many patients with small cell lung cancer initially respond to chemotherapy, they lack an effective follow-up treatment. These patients usually live a matter of weeks after their first treatment stops working and their disease returns. Scientists at NIH’s National Cancer Institute (NCI) and National Center for Advancing Translational Sciences (NCATS) teamed up to find another option to treat these cancers, which are part of a larger group of similar diseases called small cell neuroendocrine cancers.“We wanted to identify novel drugs and combinations to leverage this vulnerability therapeutically,” said NCI’s Anish Thomas, M.D., who led the study. “We saw potential opportunities because the armamentarium of new chemicals and drugs was rapidly expanding.”The NCI group collaborated with NCATS co-author Craig Thomas, Ph.D., and his team to use NCATS’ matrix screening platform and expertise to explore the potential of nearly 3,000 agents from an oncology-focused library of investigational and approved drugs against SCLC cells in the laboratory.NCATS’ robotics-enabled, high-throughput screening technologies allow scientists to rapidly test thousands of different drugs and drug combinations in a variety of ways. Scientists can examine the most promising drugs and d...
NIH     Apr 14, 2021

Study links structural brain changes to behavioral problems in children who snore


var addthis_config ={ ui_508_compliant: true}WhatA large study of children has uncovered evidence that behavioral problems in children who snore may be associated with changes in the structure of their brain’s frontal lobe. The findings support early evaluation of children with habitual snoring (snoring three or more nights a week). The research, published in Nature Communications, was supported by the National Institute on Drug Abuse (NIDA) and nine other Institutes, Centers, and Offices of the National Institutes of Health.Large, population-based studies have established a clear link between snoring and behavioral problems, such as inattention or hyperactivity, but the exact nature of this relationship is not fully understood. While a few small studies have reported a correlation between sleep apnea—when pauses in breathing are prolonged—and certain brain changes, little is known about whether these changes contribute to the behaviors seen in some children with obstructive sleep-disordered breathing (oSDB), a group of conditions commonly associated with snoring that are characterized by resistance to breathing during sleep.To address this knowledge gap, researchers led by Amal Isaiah, M.D., D.Phil., of the University of Maryland School of Medicine, capitalized on the large and diverse dataset provided by the Adolescent Brain Cognitive Development (ABCD) Study, a long-term study of child health and brain development in the United States. The team of researchers mined this wealth of data from more than 11,000 9- and 10-year-old children to examine the relationships among snoring, brain structure, and behavioral problems.Confirming the results of previous work, their statistical analysis revealed a positive correlation between habitual snoring and behavioral problems, with the children who most frequently snored generally exhibiting worse behavior according to an assessment completed by parents. The findings further showed that snoring is linked to smaller volumes ...
NIH     Apr 14, 2021

NIH trial of anti-CD14 antibody to treat COVID-19 respiratory disease begins


var addthis_config ={ ui_508_compliant: true}Colorized scanning electron micrograph of a cell (pink) infected with SARS-CoV-2 virus particles (teal), isolated from a patient sample.NIAIDA clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.The laboratory-created monoclonal antibody, called IC14, binds to a human protein, CD14, that is found on the surface of immune cells circulating in the blood and airway fluid and that also circulates as a stand-alone protein. CD14 helps immune cells recognize pathogens and injured or dying cells, alerting the immune system to danger and prompting it to respond.Research suggests that during SARS-CoV-2 infection in the lungs, CD14 overamplifies the later stages of the immune response to the virus, potentially leading to a hyperactive inflammatory response and a “cytokine storm.” Cytokines, proteins secreted by immune cells, influence the immune response. A cytokine storm is a severe immune reaction in which the body rapidly releases numerous cytokines into the blood and tissues. In COVID-19 patients, a cytokine storm may generate dangerous levels of inflammation and tissue damage in the lungs, resulting in acute respiratory distress syndrome and respiratory failure.“By blocking a protein called CD14 during the early stages of COVID-19 respiratory disease, the monoclonal antibody IC14 could potentially temper the immune system’s harmful inflammatory responses to SARS-CoV-2, thereby limiting associated tissue damage and improving patients’ health outcomes,” said NIAID Director Anthony S. Fauci, M.D.The CaTT study will enroll betw...
NIH     Apr 14, 2021